

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTY DOCKET NO.
2081-0125PAPPLICATION NO.
UnknownAPPLICANT
Kent JORGENSEN, et al.FILING DATE
FebruaryGROUP
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/G.K./	5	9	2	7	8	3	9	1998-10-27	Peterson, et al.			
	6	0	8	0	9	1	1	1996-01-16	Hong, et al.			
	4	8	2	2	3	0	2	1986-11-11	Hong, et al.			
	5	9	0	2	2	0	9	1994-04-20	Mayhew, et al.			
	6	0	3	2	2	0	2	1999-08-03	Franklin, et al.			
	6	0	8	5	1	5	9	1999-10-12	Mayhew, et al.			
	6	0	0	7	8	3	9	1999-12-28	Mayhew, et al.			
	5	8	8	2	8	7	9	1999-03-16	Needham			
	5	0	8	5	8	5	9	1999-11-16	Kozak			
	6	0	7	7	8	3	7	2000-10-24	Kozak			
	6	1	3	6	7	0	9	2000-10-24	Kozak			
/G.K./	6	1	5	8	0	0	9	2000-10-24	Kozak			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO
/G.K./	ES 2 0 3 4 0 84	1994-03-01	SPAIN				
	WO 99 0 0 0 1 0	1994-04-28	PCT				
/G.K./	WO 99 2 2 0 0 3	1994-10-13	PCT				
/G.K./	WO 99 0 2 1 2 0	1999-01-21	PCT				
/G.K./	WO 99 0 2 0 0 5	1999-01-21	PCT				
/G.K./	WO 99 1 5 7 0 1	1994-04-28	PCT				

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published).

/G.K./	"Therapeutic Activity of a Thioether-Lipid Conjugate of 1- β -D-Arabino-furanosylcytosine in Human Colorectal Cancer Xenografts", R. Herrmann, et al, Am. Assoc. Cancer Res., Vol. 52, No. 7, pp. 1865-1867 (1992)
/G.K./	"Competitive Inhibition of Lipolytic Enzymes. IX. A comparative Study on the Inhibition of Pancreatic Phospholipases A ₂ from Different Sources by (R)-2-acylamino Phospholipid Analogues", G. H. de Haas, et al, BBA - Lipids and Lipid Metabolism, NL, Elsevier Science BV., Vol. 1167, No. 3, 1993, pp. 281-288
/G.K./	"The Chemical Synthesis of a Series of Ether Phospholipids From D-Mannitol and Their Properties", J Xia, et al, Tetrahedron: Asymmetry, Vol. 8, No. 18, pp. 3131-3142, 1997

EXAMINER	/Gollamudi Kishore/	DATE CONSIDERED
		02/20/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

ATTY DOCKET NO.
2081-0125PAPPLICATION NO.
Unknown**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

APPLICANT
Kent JORGENSEN, et al.FILING DATE
February GROUP
1615**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER						DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/G.K./	5	8	5	9	2	2	8	1999-01-12	JANJIC et al.		
/G.K./	6	2	2	9	0	0	2	2001-05-08	JANJIC et al.		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)

/G.K./	"Cytotoxicity of Platelet Activating Factor and Related Alkyl-Phospholipid Analogs in Human Leukemia Cells, Polymorphonuclear Neutrophils, and Skin Fibroblasts", D. Hoffman, et al, Blood, Vol. 63, No. 3, 1984, pp. 545-552
/G.K./	"Enzymatic Degradation of Polymer Covered SOPC-Liposomes in Relation to Drug Delivery", J. Davidsen, et al, Symposium on Lipid and Surfactant Self-Assemblies: Structure, Dynamics and Reactions, Feb. 24-25, 2000, Uppsala, Sweden
/G.K./	"Controlled Destabilization of Liposomal Drug Delivery Systems by Phospholipase A ₂ ", J Davidsen, et al, Dec. 1999
/G.K./	"Increased Cell-surface Receptor Expression on U-937 Cells Induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine", M. Pushkareva, et al, Cancer Immunol Immunother (2000) 48: 569-578
/G.K./	"Ether Lipids in the Therapy of Cancer", R. Andreesen, Prog. Biochem, Pharmacol, Vol 22, pp. 118-131 1988
/G.K./	"1-β-D-Arabinofuranosylcytosine-Phospholipid Conjugates As Prodrugs of Ara-C", C. Hong, et al, Cancer Drug Delivery, Vol. 1, No. 3, 1984, pp. 181-190
/G.K./	"Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-β-D-Arabinofuranosylcytosine Conjugates of Ether Lipids", C. Hong, et al, J. Med. Chem. 1986, 29, 2038-2044
/G.K./	"Phospholipid Antitumor Agents", W. Houlihan, et al., Medicinal Research Reviews, Vol. 15, No. 3, 157-223 (1995)
/G.K./	"Antitumor Ether Lipids and Alkylphosphocholines", M. Lohmeyer, et al, Drugs of the Future, 1994, 19(11): 1021-1037
/G.K./	"Growth Arrest vs. Direct Cytotoxicity and the Importance of Molecular Structure for the In vitro Anti-Tumor Activity of Ether Lipids", M. Lohmeyer, et al, British Journal of Cancer (1995) 72, pp. 277-286
/G.K./	"Enhancement of Phospholipase A ₂ Catalyzed Degradation of Polymer Grafted PEG-Liposomes: Effects of Lipopolymer-concentration and Chain-Length", K Jorgensen, et al., Pharmaceutical Research, Vol. 16, No. 9, 1999 pp. 1491-1493
/G.K./	"Increase in Phospholipase A ₂ Activity Towards Lipopolymer-Containing Liposomes, C. Vermehren, et al, BBA, 1998, pp.27-36

EXAMINER	/Gollamudi Kishore/	DATE CONSIDERED	02/20/2008
----------	---------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LRS/KR/Sml